Bosutinib - Pfizer

Drug Profile

Bosutinib - Pfizer

Alternative Names: Bosulif; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Avillion; Massachusetts General Hospital; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class Aniline compounds; Antineoplastics; Nitriles; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 14 Jun 2018 Interim efficacy and adverse events data from a phase III BFORE trial in Chronic myeloid leukaemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 14 Jun 2018 Pooled efficacy and safety data from the phase III BFORE and BELA trials in Chronic myeloid leukaemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 14 Jun 2018 Updated safety data from a phase I/II trial in Chronic myeloid leukaemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top